Amneal Pharmaceuticals, Inc.
http://www.amneal.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Amneal Pharmaceuticals, Inc.
Amneal Launches Ready-To-Use Pemetrexed And OTC Naloxone
Amneal launched two highly anticipated products, a ready-to-use pemetrexed injectable Pemrydi and over-the-counter naloxone spray, strengthening the firm’s focus on injectables and inhalation.
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
Amneal Targets Limited US Ciprodex Pool With FDA Approval
The FDA has granted approval to Amneal’s ciprofloxacin/dexamethasone otic suspension ANDA product, referencing Ciprodex, adding a further drug to the company’s portfolio as the firm continues its strategic shift to complex generics.
FTC Sides With Amneal Over Inhaler Patent Dispute With Teva
After sending warning letters over more than 100 improper patent listings last year, the FTC has backed Amneal in its attempt to fight ProAir originator Teva over asthma inhalers.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Amedra Pharmaceuticals LLC
- Amneal Pharmaceuticals, LLC
- CorePharma LLC
- Gemini Laboratories, LLC
- Impax Generics
- Impax Laboratories, Inc. (IPXL)
- Impax Specialty Pharma
- Lineage Therapeutics Inc.
- Tower Holdings, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice